Combination treatment using adenovirus vector-mediated tumor necrosis factor-alpha gene transfer and a NF-κB inhibitor for pancreatic cancer in mice.

@article{Furukawa2011CombinationTU,
  title={Combination treatment using adenovirus vector-mediated tumor necrosis factor-alpha gene transfer and a NF-κB inhibitor for pancreatic cancer in mice.},
  author={Kenei Furukawa and Toya Ohashi and Koichiro Haruki and Yuki Fujiwara and Tomonori Iida and Hiroaki Shiba and Tadashi Uwagawa and Hiroshi Kobayashi and Katsuhiko Yanaga},
  journal={Cancer letters},
  year={2011},
  volume={306 1},
  pages={
          92-8
        }
}
Gene therapy using an adenoviral vector expressing tumor necrosis factor-alpha (TNF-α) is a new therapeutic approach for pancreatic cancer. However, the efficacy of TNF-α is limited, because it activates nuclear factor-κB (NF-κB). We investigated the combined use of AxCAhTNF-α, adenoviral vector-expressing human TNF-α, and nafamostat mesilate, a serine-protease inhibitor, a NF-κB inhibitor, using pancreatic cancer in mice. In vitro, nafamostat mesilate inhibited TNF-α-induced NF-κB activation… CONTINUE READING
BETA

Similar Papers